Backbones versus core agents in initial ART regimens: one game, two players.
Llibre, Josep M; Walmsley, Sharon; Gatell, Josep M.
J Antimicrob Chemother
; 71(4): 856-61, 2016 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-26747092
Clinical management of dyslipidaemia associated with combination antiretroviral therapy in HIV-infected patients.
Simplification to dual therapy (atazanavir/ritonavirâ+âlamivudine) versus standard triple therapy [atazanavir/ritonavirâ+âtwo nucleos(t)ides] in virologically stable patients on antiretroviral therapy: 96 week results from an open-label, non-inferiority, randomized clinical trial (SALT study).
Nucleoside reverse transcriptase inhibitor-reducing strategies in HIV treatment: assessing the evidence.
CD8(+) T Cells and cART: A Dynamic Duo?
Sentinel site active surveillance of safety of first-line antiretroviral medicines in Namibia.
Semplificazione della terapia antiretrovirale: proposta di uno score per la valutazione del paziente con viremia soppressa.
Bone Update: Is It Still an Issue Without Tenofovir Disoproxil Fumarate?
What is the effect of pill burden on adherence to HIV antiretroviral therapy?
Cyclosporine A in addition to standard ART during primary HIV-1 infection: pilot randomized clinical trial.
The dual role of pharmacogenetics in HIV treatment: mutations and polymorphisms regulating antiretroviral drug resistance and disposition.